Kornimate/medical-research-clean huggingface dataset:
esthetic outcome of isolated advancement genioplasty with and without submental liposuction in treatment of skeletal chin deficiency

Conditions: Receding Chin

Summary: this study is to measure the eshetic outcome of of isolated advancement genioplasty with and without submental liposuction in treatment of skeletal chin deficiency in double chin patients

many methods used to treat skeletal chin deficiency in double chin patients, the aim of this study is to measure the advancement genioplasty with and without submental liposuction

Eligibility criteria:
inclusion criteria: * skeletal chin deficiency * double chin patients * ages from 18 to 45 * systemic free exclusion criteria: * body mass index greater than 28 * ages greater than 45 * systemically diseased

Keywords: submental liposuction advancement genioplasty double chin patients
extension study of biostate in subjects with von willebrand disease

Conditions: Von Willebrand Disease

Summary: the aim of the von willebrand disease (vwd) therapy is to treat and prevent bleeding episodes due to abnormal platelet adhesion and abnormal blood coagulation as a result of low or abnormal von willebrand factor (vwf) and/or factor viii (fviii) levels. the long-term efficacy and safety of a vwf/fviii concentrate, biostate, will be investigated in children, adolescents, and adults with vwd in whom treatment with a vwf product is required for prophylactic therapy, haemostatic control during surgery, or control of a non-surgical, spontaneous, or traumatic bleeding event.


Eligibility criteria:
inclusion criteria: * have completed study cslct-bio-08-52 (assessment of efficacy and safety of biostate in paediatric subjects with von willebrand disease) or study cslct-bio-08-54 (assessment of efficacy and safety of biostate in adolescent or adult subjects with von willebrand disease). * the subject and/or his/her legal guardian understand(s) the nature of the study and has/have given written informed consent to participate in the study and is/are willing to comply with the protocol. exclusion criteria: * early discontinuation of a subject from the main studies cslct-bio-08-52 or cslct-bio-08-54. * mental condition rendering the subject (or the subject's legal guardian) unable to understand the nature, scope and possible consequences of the study. * any condition that is likely to interfere with evaluation of the imp or satisfactory conduct of the study. * are not willing and/or not able to comply with the study requirements. * employee at the study site, or spouse/partner or relative of the investigator or subinvestigators. * female subjects of childbearing potential either not using, or not willing to use, a medically reliable method of contraception for the entire duration of the study, or not sexually abstinent for the entire duration of the study, or not surgically sterile. * intention to become pregnant during the course of the study. * pregnancy, or nursing mother.

Keywords: von willebrand disease
locally advanced nsclc hyperfractionated rt

Conditions: Carcinoma, Non Small Cell Lung (NSCLC)

Summary: this is a prospective phase ii study designed to evaluate an accelerated and adaptive rt approach for locally-advanced non-small cell lung cancer (nsclc). all eligible subjects will have an interim pet-ct during radiation therapy to determine the metabolic complete response rate. radiation therapy will be given in an accelerated fashion (2 gy/fraction, 6 fractions/week) with concurrent chemotherapy. interim responses will be assessed using percist criteria. despite concurrent chemotherapy and radiation therapy, local/regional failure occurs in \~50% of patients with locally-advanced nsclc. clinical studies have demonstrated that accelerated fractionation (giving the same total dose in a shorter period of time) improves outcomes in several malignancies, including lung cancer. administering higher than conventional doses of rt to all sites of original disease leads to inferior outcomes. adapting the rt approach, giving a higher dose to slowly responding disease as assessed with interim pet has been shown to be feasible. percist (positron emission tomography response criteria in solid tumors) provides guidelines on how to report responses to therapy based on pet-ct. pet-ct response has been shown to be prognostic in a variety of clinical scenarios in lung cancer including after induction therapy. in one study, pet was performed after neoadjuvant chemoradiotherapy (40-50.4 gy). complete or partial metabolic response using percist criteria was predictive of loco-regional, distant, and overall progression-free survival.


Eligibility criteria:
inclusion criteria: 1. histologic/cytologic documentation of non-small cell lung cancer (nsclc) 2. unresectable stage ii, iiia, or iiib disease 3. zubrod/ecog performance status 0-1 4. weight loss \< 10% in preceding 3 months prior to diagnosis 5. adequate organ function defined as the following 6. absolute neutrophil count of ≥ 1,500 and platelet count ≥ 100,000 7. cockcroft calculated creatinine clearance of ≥ 45 ml/min or 1.5 x the upper limit of normal (uln) 8. a total bilirubin ≤ 1.5 uln, aspartate aminotransferase (ast) ≤ 2.0 x uln 9. ≥ 18 years of age. 10. negative pregnancy test in women of child-bearing potential 11. signed study-specific informed consent. 12. no prior chemotherapy or radiotherapy for nsclc 13. no prior mediastinal or thoracic radiation exclusion criteria: 1. prior thoracic irradiation. 2. medical contraindications to thoracic irradiation. 3. pre-existing sensory neuropathy of grade ≥ 2 4. pleural effusion: when pleural fluid is visible on both ct scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative. patients with effusions that are minimal (i.e. not visible on chest x-ray) or that are too small to safely tap are eligible 5. patients with contralateral hilar involvement
efficacy of g-csf in the management of steroid non-responsive severe alcoholic hepatitis

Conditions: Severe Alcoholic Hepatitis

Summary: after successful screening, first the investigators first treat patients of severe alcoholic hepatitis with steroids for 7 days. patients who are found to be unresponsive as per lille's score \[\>0.45\] would be randomized into either placebo group or g-csf group. responders to steroids will continue on steroids for 28 days followed by 2 weeks of tapering. non responders will be randomized to receive g-csf for 28days.


Eligibility criteria:
inclusion criteria: - severe alcoholic hepatitis patients \[maddrey's score \> 32\] aged between 18 to 65 years. exclusion criteria: * presence of active infections * acute gi bleed * hepatorenal syndrome * patient unwilling * df\>120 * autoimmune hepatitis * hepatitis b, hepatitis c, hiv cases * pregnancy
weight watchers and families

Conditions: Overweight and Obesity

Summary: research suggests that when one spouse loses weight, the other spouse does too. this study will examine whether a ripple effect is observed in untreated spouses and children of individuals participating in a nationally available weight loss program. participants will be randomly assigned to either receive weight watchers immediately or at the end of a 6-month waiting period. participants and untreated spouses (and any children in the home) will be assessed at baseline, 3, and 6 months.


Eligibility criteria:
inclusion criteria: * body mass index between 27.0-40.0 kg/m2 * married or living with a significant other who had a bmi \> 25 kg/m2 exclusion criteria: * currently in a weight loss program, dieting, or taking medications that might affect weight * had participated in a weight loss program in the past year * lost \> 5% of their body weight in the past 6 months * were planning to or had undergone weight loss surgery * had any orthopedic limitations or contraindications to physical activity * were pregnant, lactating, or less than 6 months postpartum, or were planning to become pregnant in the next year * reported uncontrolled hypertension, history of coronary heart disease, stroke, or peripheral arterial disease; reported chronic gastrointestinal disease * endorsed having hepatitis b or c, cirrhosis, or hiv * had a history of cancer within the past 5 years * reported a significant psychiatric illness that might interfere with completion of the study.
feasability test of a handset device to detect levels of sedation and loss of consciousness

Conditions: Conscious Sedation

Summary: sedation is often administered to relieve anxiety and discomfort during uncomfortable procedures in elderly patients. patient control of sedation offers many potential benefits for patients and healthcare professionals, including improved safety and patient satisfaction. the investigators overall goal is to develop a patient controlled intravenous sedation system that is effective but very safe for the patient, and requires minimal supervision by a doctor or nurse. to fulfill these criteria, a sedation system should incorporate fail-safe safety mechanisms. a key safety-critical component is a method of objectively assessing the degree of sedation of the patient, and of preventing him from self-administering unsafe doses of the sedative drug. the investigators have designed a new sedation system that uses a measure of the speed of response of the patient to a defined non-noxious stimulus to determine whether or not it is safe to allow him to self-administer further levels of sedation. before being able to execute a volunteer study in order to determine a rational selection of optimal threshold response time, a feasibility test on the handset device is required.


Eligibility criteria:
inclusion criteria: * age 50-72 years exclusion criteria: * volunteer refusal * patient age \>72 years * significant cardiovascular or respiratory disease * latex allergy

Keywords: sedation
dynamics of organ damage and immune exhaustion during sepsis

Conditions: Sepsis

Summary: this is a prospective, non-randomized study investigating if organ damage and immune changes can be measured by liquid biopsy ngs through advanced analytical methods.

to determine the sample size needed to derive a signature matrix to identify novel biomarkers in sepsis, investigators performed a mathematical modeling exercise of the lower limits of sensitivity of this liquid biopsy approach. the detection limit of cell-free nucleic acid analysis is determined in part by the number of independent transcripts or "reporters" that are interrogated. using an established and independently validated binomial model that was previously applied to the prediction of circulating tumor nucleic acid detection limits, investigators estimated the probability of cell-free nucleic acid detection in sepsis patients based on the number of unique tissue-specific reporters (i.e., hepatic transcripts that may reflect disease severity). this yields a result of n=18 per group to achieve 0.90 power at alpha=0.05. the investigators will thus plan to analyze data from n=18 per cell/tissue type to derive the signature matrix for this project.

Eligibility criteria:
inclusion criteria: • patients who've developed a shocked state (hypotension or lactate grade \>4) or clinical concern exclusion criteria: * \<18 years of age * pregnant women * nursing women

Keywords: sepsis
impact of periodontal therapy on af recurrence post-ablation in high-inflammatory burden patients

Conditions: Atrial Fibrillation; Periodontitis

Summary: comparison of non-surgical periodontal therapy versus background periodontal care in reducing atrial fibrillation recurrence in patients with af and periodontitis: a randomized trial with two arms (background therapy group vs. conventional non-surgical therapy group).


Eligibility criteria:
inclusion criteria: - age ≥18 years. diagnosed with atrial fibrillation (af) and undergoing first-time catheter ablation. diagnosed with periodontitis (2017 world workshop classification) and periodontal inflamed surface area (pisa) \>500 mm². willing and able to provide written informed consent. exclusion criteria: - requiring periodontal surgical intervention, e.g., flap surgery, bone grafting. non-surgical periodontal therapy (e.g., scaling and root planing) within the past 6 months. active systemic infection, e.g., sepsis, tuberculosis. current immunosuppressive therapy, e.g., post-transplant medications, long-term corticosteroids. chronic hepatitis b or hiv infection. chronic systemic antibiotic use (\>4 weeks). pregnancy or lactation. anticipated survival \<12 months.

Keywords: atrial fibrillation periodontitis
a phase ii study of fruquintinib combined with capecitabine as first-line treatment for advanced metastatic colorectal cancer unsuitable for intravenous chemotherapy

Conditions: Unresectable Metastatic Colorectal Cancer

Summary: this is a single center, open-labeled, single arm phase ii study aimed to investigate the efficacy and safety of fruquintinib combined with capecitabine as first-line treatment for advanced metastatic colorectal cancer patients unsuitable for intravenous chemotherapy.

fruquintinib is an oral small molecule inhibitor of vegfr1/2/3, this phase ii study aimed to investigate the efficacy and safety of fruquintinib combined with capecitabine as first-line treatment for advanced metastatic colorectal cancer patients of elderly or those unsuitable for intravenous chemotherapy.

Eligibility criteria:
inclusion criteria: 1. ≥18 years old at the time of signing the informed consent; 2. histologically or cytologically confirmed unresectable metastatic colorectal cancer; 3. haven't received systematic therapy after diagnosis of metastatic colorectal cancer; 4. intolerable to standard treatment of oxaliplatin- or irinotecan-based intravenous combination therapy; 5. at least one measurable lesion(s); 6. ecog ps 0-2; 7. life expectancy≥3 months; 8. adequate organ and bone marrow functions; 9. women of childbearing age must have a negative pregnancy test within the first day of the study, and contraceptive methods should be taken during the study until 6 months after the last administration; 10. willingness and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure. exclusion criteria: 1. previous treatment with vegfr inhibition; 2. participating in other drug clinical trials within 4 weeks before recruited; 3. have received other systemic anti-tumor therapies within 4 weeks before recruited; 4. non-controlled hypertension after monotherapy, that is, systolic blood pressure \> 140mmhg or diastolic blood pressure \> 90mmhg; 5. proteinuria ≥ 2+ (1.0g/24hr); 6. clinically significant electrolyte abnormality; 7. clinically significant cardiovascular diseases; 8. thromboembolism or arteriovenous events occurred 6 months before recruited; 9. ≥grade 3 bleeding events 4 weeks before recruited; 10. evidence of cns metastasis; 11. active gastric and duodenal ulcer, ulcerative colitis or uncontrolled hemorrhage in gi; 12. active, symptomatic interstitial lung disease causing dyspnea (≥ grade 2 dyspnea), pleural effusion or ascites; 13. history of organ transplantation; 14. aptt \>1.5×uln or inr\>1.5; 15. history of hiv infection or active hepatitis b / c; 16. allergic to fruquintinib and / or capecitabine; 17. pregnant or lactating women; 18. clinically detectable secondary primary malignancies at the time of enrollment (excluding fully treated basal cell carcinoma of the skin or carcinoma in situ of the cervix); 19. patients who are not suitable for the study judged by the researchers.
cranial ultrasound for point of care intracranial pathology detection in pediatrics

Conditions: Traumatic Brain Injury

Summary: to improve patient selection for head ct, a safe and high sensitivity screening neuroimaging modality is needed. currently many clinicians must make treatment decisions based solely on the patients clinical exam, which has low sensitivity and specificity and low inter-rater reliability. this study is being done to learn more about b-mode cranial point-of-care ultrasound (cpocus). ultrasound has several advantages. it is a safe, non- invasive, low-cost, fast and portable bedside tool without ionizing radiation exposure.

b-mode cranial point-of-care ultrasound (cpocus) being used in this study is an innovative, low-risk, inexpensive solution for diagnosing clinically significant intracranial pathology in children presenting with blunt head trauma which could be valuable for resource- austere environments. traumatic brain injury remains a leading cause of death and disability in children. in addition, those who present with suspected acute brain injury in resource-austere environments may be at high risk of long-term neurologic sequelae or death. early neuroimaging to identify traumatic brain injury and guide interventions is key to preventing their neurologic morbidity and mortality.

Eligibility criteria:
inclusion criteria: * patients requiring a head computed tomography (ct) as the standard of care * seen in the pediatric emergency department or pediatric intensive care unit at atrium health wake forest brenner children's hospital or levine children's hospital exclusion criteria: * patients with open skull fractures * previous hemicraniectomy * existing surgical defect in the skull * patients being transitioned to comfort care

Keywords: head injury imaging pediatrics
classification and assessment of mental health performance using schematics

Conditions: Suicide Ideation; Suicidal Intention; Suicide and Depression

Summary: this is an open enrollment study to collect data for the optimization of smartphone-based algorithms for the early detection of mental health and suicidal risk in a student population. approximately 2000 students, ages 8-23, will be recruited by therapists across 30 schools and mental health centers.


Eligibility criteria:
inclusion criteria: * currently a client receiving services from mental health agency at a school or outpatient, or at a college/university counseling center * age ≥ 8 years and \< 23years * able to provide informed consent, parental permission or assent * english as a primary language exclusion criteria: * participants with communication disorders (linguistic or articulation) * any minor participants for whom parental or legal guardian consent cannot be obtained. * history of any other serious medical or psychiatric condition that would interfere with the ability of the patient to complete the study or would make it ethically unfeasible to enroll them * participants with an intellectual disability that the therapist deems a barrier to participation
the effect of a perinatal health promotion program on the different levels of gestational hyperglycemic women

Conditions: Gestational Diabetes

Summary: taiwan national health insurance system was launched in 1995 and the diagnosis and treatment for gestational diabetes mellitus were reimbursed. however, controversy regarding treatment and prevention programs for the other different levels of gestational hyperglycemia continues. moreover, long-term follow-up studies for the impact of different levels of gestational hyperglycemia on women's perinatal consequences were not found. thus, the purpose of the study, is to explore the effect of a perinatal health promotion program on three different levels of gestational hyperglycemic women's bio-psycho-social features and their offspring's development.

the investigators will recruit 120 women with three different levels of gestational hyperglycemia and assign them to either experimental group (a total of 60 women of gestational hyperglycemia) or control group (a total of 60 women of gestational hyperglycemia). data will be collected at the women's six-month gestation, hospitalization for childbirth, and six weeks, six months, and one year postpartum. the three-year study findings can demonstrate the consequences and risk factors for women with three different levels of gestational hyperglycemia to suffer from type 2 diabetes mellitus. in addition, the results can be taken as an evidence-based intervention for the perinatal health promotion program in preventing the gestational hyperglycemic women to suffer from type 2 diabetes mellitus and in decreasing the impact of gestational hyperglycemia on the development of the gestational hyperglycemic women's offspring.

Eligibility criteria:
inclusion criteria:the woman who * is 20 years old or above. * has a positive test for gestational diabetes mellifluous with the 75% oral glucose tolerance test during 24\~28 gestation. * has junior high or above educational level. * can speak mandarin chinese. * is taiwanese residence. * plans to give a childbirth at the medical center. exclusion criteria:the woman who -is immigrant.
volumes of administration for intranasal midazolam

Conditions: Children Requiring Sedation to Facilitate Laceration Repair

Summary: the purpose of this study is to determine exactly how much drug volume should be administered into each nare, so that the drug absorption can be maximized and the amount that runs out of the nose, or is swallowed, is minimized, thereby optimizing the effectiveness of any drug given intranasally. the investigators will determine this ideal "volume of administration" by studying intranasal midazolam in children who require sedation to facilitate laceration repairs. the investigators will evaluate both clinical outcomes as well as pharmacokinetic outcomes associated with each volume of administration. we will block randomize children to receive intranasal midazolam in maximum aliquots of one of the three following voa: 200 microliters (mcl), 500 mcl, or 1000 mcl.

the intranasal route is an effective means of administering sedative medications for children. however, sometimes the child has to receive a certain dose that requires a very large volume to be administered into the nose, because of the types of concentrations of drugs that are available. most drugs are not concentrated enough so that small volumes can be consistently given, so as a result, sometimes a very large amount of medication is administered intranasally. when the amount is too large, most of the medication either runs back out the nose, or down the back of the nose and throat and is swallowed, instead of being absorbed in the nasal cavity, where it can be quickly absorbed and produce optimal effectiveness.

Eligibility criteria:
inclusion criteria: * 1 to 7 years of age, inclusive. * require intranasal midazolam for minimal sedation to facilitate laceration repair. exclusion criteria: * weight less than 10 kg. * known allergy to midazolam. * presence of intranasal obstruction (e.g. mucous or blood) that cannot be readily cleared * inability to speak english or spanish * developmental delay, psychiatric illness, neurologic impairment, or altered mental status; or illnesses associated with chronic pain (e.g. sickle cell disease, inﬂammatory bowel disease). * foster children or wards.

Keywords: sedation laceration repair children intranasal midazolam
danish study of optimal acute treatment of patients with st-elevation myocardial infarction

Conditions: ST Segment Elevation Myocardial Infarction

Summary: this study focuses on cardioprotective strategies.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * acute onset of chest pain of \< 12 hours' duration. * st-segment elevation ≥ 0.1 mv in ≥ 2 contiguous leads, signs of a true posterior infarction or documented newly developed left bundle branch block. culprit lesion in a major native vessel. exclusion criteria: * pregnancy. * known intolerance of asa, clopidogrel, heparin or contrast. * inability to understand information or to provide informed consent. * haemorrhagic diathesis or known coagulopathy. * stent thrombosis.

Keywords: stemi ischemic postconditioning deferred stenting primary pci